Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2010 2
2011 4
2012 3
2013 3
2014 5
2015 1
2016 2
2017 1
2018 3
2019 3
2020 1
2021 6
2022 7
2023 12
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
Hanania NA, Castro M, Bateman E, Pavord ID, Papi A, FitzGerald JM, Maspero JF, Katelaris CH, Singh D, Daizadeh N, Altincatal A, Pandit-Abid N, Soler X, Siddiqui S, Laws E, Jacob-Nara JA, Rowe PJ, Lederer DJ, Hardin M, Deniz Y. Hanania NA, et al. Among authors: altincatal a. Ann Allergy Asthma Immunol. 2023 Feb;130(2):206-214.e2. doi: 10.1016/j.anai.2022.10.018. Epub 2022 Nov 2. Ann Allergy Asthma Immunol. 2023. PMID: 36332763 Free article. Clinical Trial.
Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.
Berger P, Menzies-Gow A, Peters AT, Kuna P, Rabe KF, Altincatal A, Soler X, Pandit-Abid N, Siddiqui S, Jacob-Nara JA, Deniz Y, Rowe PJ. Berger P, et al. Among authors: altincatal a. Ann Allergy Asthma Immunol. 2023 Feb;130(2):215-224. doi: 10.1016/j.anai.2022.11.006. Epub 2022 Nov 7. Ann Allergy Asthma Immunol. 2023. PMID: 36356712 Free article. Clinical Trial.
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
Corren J, Katelaris CH, Castro M, Maspero JF, Humbert M, Halpin DMG, Altincatal A, Pandit-Abid N, Soler X, Radwan A, Jacob-Nara JA, Deniz Y, Rowe PJ. Corren J, et al. Among authors: altincatal a. ERJ Open Res. 2023 Oct 16;9(5):00037-2023. doi: 10.1183/23120541.00037-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37859672 Free PMC article.
Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.
Pavord ID, Casale TB, Corren J, FitzGerald MJ, Deniz Y, Altincatal A, Gall R, Pandit-Abid N, Radwan A, Jacob-Nara JA, Rowe PJ, Busse WW. Pavord ID, et al. Among authors: altincatal a. J Allergy Clin Immunol Pract. 2024 Jul;12(7):1763-1772. doi: 10.1016/j.jaip.2024.03.031. Epub 2024 Mar 29. J Allergy Clin Immunol Pract. 2024. PMID: 38555079 Free article. Clinical Trial.
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A, Castro M, Corren J, Pavord ID, Tohda Y, Altincatal A, Pandit-Abid N, Laws E, Akinlade B, Mannent LP, Gall R, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M. Papi A, et al. Among authors: altincatal a. Respir Med. 2024 Apr;224:107535. doi: 10.1016/j.rmed.2024.107535. Epub 2024 Jan 23. Respir Med. 2024. PMID: 38272376 Free article.
Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study.
Bacharier LB, Guilbert TW, Katelaris CH, Deschildre A, Phipatanakul W, Liu D, Altincatal A, Mannent LP, Amin N, Laws E, Akinlade B, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M. Bacharier LB, et al. Among authors: altincatal a. J Allergy Clin Immunol Pract. 2024 Apr;12(4):948-959. doi: 10.1016/j.jaip.2023.12.006. Epub 2023 Dec 11. J Allergy Clin Immunol Pract. 2024. PMID: 38092225 Free article. Clinical Trial.
50 results